Acne News and Research RSS Feed - Acne News and Research

Acne is a disorder resulting from the action of hormones and other substances on the skin's oil glands (sebaceous glands) and hair follicles. These factors lead to plugged pores and outbreaks of lesions commonly called pimples or zits. Acne lesions usually occur on the face, neck, back, chest, and shoulders. Although acne is usually not a serious health threat, it can be a source of significant emotional distress. Severe acne can lead to permanent scarring.
Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan plc, a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration to market ACZONE (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. [More]
First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017. [More]
Early strength training could help prevent ACL injuries in young women

Early strength training could help prevent ACL injuries in young women

Young women demonstrate less strength and neuromuscular control after puberty, and this may make them particularly susceptible to Anterior Cruciate Ligament (ACL) injuries, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif. [More]
Perrigo closes previously announced acquisition of generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo closes previously announced acquisition of generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo Company plc announced today that it has completed the previously announced acquisition of a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, LLC. [More]

Perrigo to acquire generic Retin-A portfolio from Matawan Pharmaceuticals

Perrigo Company plc announced today that it will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, LLC. Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. [More]
Women with moderate-to-severe PMS at increased risk of developing high blood pressure in later life

Women with moderate-to-severe PMS at increased risk of developing high blood pressure in later life

In the first prospective study to consider premenstrual syndrome (PMS) as a possible sentinel for future risk of hypertension, epidemiologist Elizabeth Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at the University of Massachusetts Amherst and the Harvard School of Public Health report that women with moderate-to-severe PMS had a 40 percent higher risk of developing high blood pressure over the following 20 years compared to women experiencing few menstrual symptoms. [More]

Syneron Medical reports revenue of $62.1 million for third quarter 2015

Syneron Medical Ltd., a leading global aesthetic device company, today announced financial results for the three month period ended September 30, 2015. [More]
LEO Pharma enters into Asset Purchase Agreement to acquire Astellas’ global dermatology business

LEO Pharma enters into Asset Purchase Agreement to acquire Astellas’ global dermatology business

LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million. [More]
Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP. [More]
Physicians leave severe acne patients on ineffective antibiotics for too long before prescribing more potent drug

Physicians leave severe acne patients on ineffective antibiotics for too long before prescribing more potent drug

A medical records analysis by researchers at NYU Langone Medical Center concludes that physicians who treat severe acne leave too many patients on ineffective antibiotics for far too long before prescribing more potent needed therapy with the medication isotretinoin, sometimes known by its former brand name Accutane. [More]
Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Mallinckrodt plc, a leading specialty biopharmaceutical company, today announced that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology 2015 Annual Meeting to be held November 7-11 in San Francisco. [More]
Survey: One-third of US women use compounded hormones at menopause

Survey: One-third of US women use compounded hormones at menopause

A third of US women who take hormones at menopause are using compounded hormones, shows a new national survey. These women commonly--and mistakenly--think these hormones are safer and offer more benefits than FDA-approved therapies. [More]
GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung [More]
Weight loss and exercise improve ovulation in women with polycystic ovary syndrome

Weight loss and exercise improve ovulation in women with polycystic ovary syndrome

Weight loss and exercise improve ovulation in women who have polycystic ovary syndrome, a common hormone disorder that often causes infertility, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism. [More]
Stoptober campaign focuses on skin disease research

Stoptober campaign focuses on skin disease research

Stoptober is a UK-wide campaign to get the nation to quit smoking. We, the British Skin Foundation, are asking that Stoptober participants get a friends, family & colleagues to sponsor your efforts and raise some money for skin disease research at the same time. [More]
Researchers report significant progress in management of patients with dry eyes

Researchers report significant progress in management of patients with dry eyes

Do you have problems with dry eyes? If so, you're not alone--it's one of the most common reasons for patient visits to eye care professionals. Recent years have seen significant progress in management of patients with dry eyes, according to the September special issue of Optometry and Vision Science, official journal of the American Academy of Optometry. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
New TSRI discovery could open way to incorporate sulfur into natural antibiotic products

New TSRI discovery could open way to incorporate sulfur into natural antibiotic products

In a discovery with implications for future drug design, scientists from the Florida campus of The Scripps Research Institute have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity. [More]

Syneron Medical's second quarter 2015 revenue up 14% to $73.5 million

Syneron Medical Ltd., a leading global aesthetic device company, today announced financial results for the three month period ended June 30, 2015. [More]
Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology. [More]
Advertisement
Advertisement